The historical roots of the current avoidance of MAOIs are reviewed. A practical approach to the careful prescription of MAOIs is outlined. Medical contraindications, side effects and their management and drug and food interactions with MAOIs are discussed. With careful patient selection, adequate caution by the physician, and appropriate preparation of the patient, MAOIs are often uniquely effective (as in endogenous anxiety) and have an acceptably low potential for serious toxicity.
Get full access to this article
View all access options for this article.
References
1.
CraneG. E., Iproniazid Phosphate (Marsilid), A Therapeutic Agent for Mental Disorders and Debilitating Diseases, Psychiatr. Res. Rep., 8, pp. 142–152, 1957.
2.
ZellerE.BarskyJ.FoutsJ. R.KirsheimerW. F.Van OrdenL. S., Influence of Isonicotinic Acid Hydrazine (INH) and 1-Isonicotinyl 2-Isopropyl Hydrazine (11 H) on Bacterial and Mammalian Enzymes, Experientia, 8, pp. 349–350, 1952.
3.
OglivieC., The Treatment of Pulmonary Tuberculosis with Iproniazid and Isoniazid, Quart. J. Med., 24, pp. 175–189, 1955.
4.
BlackwellB.MarleyE.PriceJ.TaylorD., Hypertensive Interactions Between MAO Inhibitors and Foodstuffs, Brit. J. Psychiat., 113, pp. 349–365, 1967.
5.
Clinical Psychiatry Committee of the Medical Research Council, Clinical Trial of the Treatment of Depressive Illness, Brit. Med. J., 1, p. 881, 1965.
6.
WestE. M.DallyP. J., Effects of Iproniazid in Depressive Syndromes, Brit. Med. J., 1, pp. 1491–1494, 1959.
7.
SargantW., The Treatment of Anxiety States and Atypical Despressions by the Monoamine Oxidase Inhibitor Drugs, J. Neuropsychiatry (Suppl.), 3, pp. 96–103, 1962.
8.
TyrerP.CandyJ.KellyD., Phenelzine in Phobic Anxiety: A Controlled Trial, Psychol. Med., 3, pp. 120–124, 1973.
9.
SheehanD. V.BallangerJ.JacobsonG., The Treatment of Endogenous Anxiety with Phobic, Hysterical and Hypochondriacal Symptoms, 37, pp. 51–59, 1978.
10.
SheehanD. V.SheehanK. E., The Classification of Anxiety and Hysterical States, For Publication 1980.
11.
FeighnerJ. P.RobinsE.GuzeS. B.WoodruffR. A.WinokurG.MunozR., Diagnostic Criteria for Use in Psychiatric Research, Arch. Gen. Psychiat., 26, pp. 57–63, 1972.
12.
SpitzerR. L.EndicottJ.RobinsE., Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders, Second Edition, New York State Psychiatric Institute Biometrics Research, 1975.
13.
YoudimM. B. H.CollinsG. G. S.SandlerM., Multiple Forms of Rat Brain Monoamine Oxidase, Nature (Lond.), 223, pp. 626–628, 1969.
14.
EdwardsD. J., Monoamine Oxidases in Brain and Platelets: Implications for the Role of Trace Amines and Drug Action, UstinE.SandlerM. (eds.), Trace Amines and the Brain, Marceo Dekker, New York, pp. 59–81, 1976.
15.
AntonaccioM. J.SmithC. B., Effects of Chronic Pretreatment with Pargyline Upon Responses of the Atrial Pacemaker and of Left Atrial Stress of Guinea Pigs to Tyramine, Mephenetermine, d-Amphetamine and Adrenergic Nerve Stimulation, J. Pharmacol. Exp. Ther., 170, pp. 97–107, 1969.
16.
ColeJ. O.DavisG. M., Antidepressant Drugs, FreedmanA. M.KaplanH. I.SadockB. J. (eds.), Comprehensive Textbook of Psychiatry II, Williams and Wilkins, Baltimore, p. 1947, Chapter 31.2, 1975.
17.
GirdwoodR. H., Death After Taking Medicaments, Brit. Med. J., 1, pp. 501–504, 1974.
18.
FreedmanD. M.KaplanH. I.SadockB. J., ECT Mortality, Cited in Comprehensive Textbook of Psychiatry, Second Edition, Vol. 2, p. 1942, 1975.
19.
NatoffI. L., Toxic Reactions to Foodstuffs During Therapy With Monoamine Oxidase Inhibitors, Med. Proc., 11, pp. 101–104, 1965.
20.
JohnstoneE. C.MarshW., Acetylator Status and Response to Phenelzine in Depressed Patients, Lancet, 1, pp. 567–570, 1973.
21.
HutchinsonJ. T.SmedbergD., Treatment of Depression: Comparative Study of ECT and Six Drugs, Brit. J. Psychiatry, 109, pp. 536–538, 1963.
22.
LingeE. A., Combined Drug Therapy Compared with Electric Shock in Psychotic Depression, Amer. J. Psychiatry, 120, pp. 808–810, 1964.
23.
DunleavyD. L. F.OswaldI., Phenelzine, Mood Response and Sleep, Archives of General Psychiatry, 28, pp. 353–356, 1973.
24.
SheehanD. V.SheehanK. E., The Classification of Phobic Disorders, Submitted for publication 1980.
25.
RobinsonD. S.NiesA.RavarisC. L.IvesD.BartlettD., Clinical Pharmacology of Phenelzine, Arch. Gen. Psychiat., 35, pp. 629–638, 1978.
26.
KievA., Somatic Manifestations of Depressive Disorders, Excerpta. Medica., International Congress Series No. 332, 1974.
27.
AsatoorA. M.LeviA. J.MilneM. D., Tranylcypromine and Cheese, Lancet., ii, pp. 733–734, 1963.
28.
BlackwellB., Hypertensive Crisis Due to MAO Inhibitors, Lancet, ii, pp. 849–851, 1963.
29.
BlackwellB., Clinical and Pharmacological Interactions of MAO Inhibitors, Amines and Foodstuffs, M.D. Thesis, Cambridge University, 1966.
30.
BlackwellB.MarleyE., Interactions of Cheese and Its Constituents with MAO Inhibitors, Brit. J. Pharmacol., 26, pp. 120–141, 1966.
31.
BlackwellB.MarleyE., Interactions of Yeast Extracts and Their Constituents with MAO Inhibitors, Brit. J. Pharmacol., 26, pp. 142–161, 1966.
32.
SchildkrautJ. J.KleinD. F., The Classification and Treatment of Depressive Disorders, ShaderR. I. (ed.), Manual of Psychiatric Therapeutics, Little Brown and Co., Boston, Massachusetts, p. 61, 1975.
33.
RosenblumL. E.KornR. J.ZimmermanH. J., Hepatocellular Jaundice As a Complication of Iproniazid Therapy, Arch. Int. Med.105:, pp. 583–593, 1960.
34.
HollisterL., Complications from Psychotherapeutic Drugs III, New England J. Med., 264, pp. 399–400, 1961.
35.
SjogvistF., Interaction Between MAO Inhibitors and Other Substances, Proc. Roy. Soc. Med., 58, pp. 967–978, 1965.
36.
ElisJ.LaurenceD. R.MattieH.PrichardB. N. C., Modification by MAO Inhibitors of the Effect of Some Sympathomimetics on Blood Pressure, Brit. Med. J., 2, pp. 75–78, 1967.
37.
BoakesA. J.TeohD. C.BararF. S. K.BenedikterL. T.PrichardB. N. C., Interaction Between Sympathomimetic Amines and Antidepressant Agents in Man, Brit. Med. J., 1, pp. 311–315, 1973.
38.
SvedmyrN., The Influence of Atricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Non-Adrenaline and Adrenaline in Man, Life Sciences, 7, pp. 77–84, 1968.
39.
BoakesA. J.LaurenceD. R.LovelK. W.O'NeilR.VerrillP. J., Adverse Reactions to Local Anesthetic/Vasoconstrictor Preparation, British Dental Journal, 133, pp. 137–140, 1972.
40.
American Pharmaceutical Association Monographs: The National Society of Pharmacists. Evaluations of Drug Interactions: Insulin-Phenelzine, 2nd edition, pp. 110–112, 1976.
41.
PontoL. B.PerryP. J.LiskowB. I.SeabaH. H., Drug Therapy Review: Tricyclic Antidepressant and MAO Inhibitor Combination Therapy, Amer. J. Hosp. Pharm., 34, pp. 954–961, 1977.
42.
SpikerD. G.PughD. D., Combining Tricyclic and MAO Inhibitor Antidepressants, Arch. Gen. Psychiatry, 33, pp. 828–830, 1976.
43.
AshcroftG. W., Psychological Medicine: Management of Depression, Brit. Med. J., 2, pp. 372–376, 1975.
44.
PareC. M. B., Treatment of Depression, Lancet, 1, pp. 923–925, 1965.
45.
LaRocheM. J.BrodieB. B., The Lack of Relationship Between the Inhibition of Monoamine Oxidase and the Potentiation of Hexobarbital Hypnosis, J. Pharmacol. Exp. Ther., 130, pp. 134–137, 1960.
46.
KlineN. S., Depression: Its Diagnosis and Treatment, Brunner/Mazel, New York, p. 38, 1969.
47.
SimmonsA. V.CarrD.RossE. J., Case of Self-Poisoning with Multiple Antidepressant Drugs, Lancet, 1, p. 214, 1970.
48.
GoodmanL. S.GillmanA., The Pharmacological Basis of Therapeutics, 5th Ed., MacMillan Pub. Co., New York, p. 182.
49.
ArenaJ. M.PoisoningT. M.–Treatment and Prevention, JAMA, 232, pp. 1272–1275, 1975.
50.
KlineN. S.AlexanderS.ChamberlinA., Psychotropic Drug Manual for Emergency Management of Overdosage (Psychiatric Durg Memo), Medical Economics, Oradell, New Jersey, 1974.
51.
DoneA. K., Pharmacology for Physicians, Chapter on Pharmacologic Principles in the Treatment of Poisoning, American Society for Pharmacology and Experimental Therapeutics, Inc., 1969.
52.
Koch-WeserJ., General Considerations and Principles of Management of Chemical Intoxications, ThornG. N. (eds.), Harrison's Principles of Internal Medicine, 8th ed., McGraw Hill, New York, p. 688, Chapter 115, 1977.
53.
VersacciA. A.NakamotoS.KoeffW. J., Phenelzine Intoxication, Report of a Case Treated by Hemodialysis, Ohio State Medical Journal, 60, pp. 770–771, August 1964.
54.
BatemanC. B., Fatalities from Overdosage of Antidepressant Drugs, Can. Med. Assn. J., 85, p. 759, 1961.
55.
McCaigJ. N.EdmondsonJ. S., Overdose of Parstelin, Brit. Med. J., 5439, p. 923, 3 April 1965.
